These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30258212)

  • 21. Loss of lower extremity bone mineral density 1 year after denosumab is discontinued in persons with subacute spinal cord injury.
    Cirnigliaro CM; La Fountaine MF; Parrott JS; Kirshblum SC; Sauer SJ; Shapses SA; McClure IA; Bauman WA
    Osteoporos Int; 2023 Apr; 34(4):741-748. PubMed ID: 36735054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
    J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma.
    Satoh T; Kimura M; Matsumoto K; Tabata K; Okusa H; Bessho H; Iwamura M; Ishiyama H; Hayakawa K; Baba S
    Cancer; 2009 Aug; 115(15):3468-74. PubMed ID: 19484786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.
    Israeli RS; Rosenberg SJ; Saltzstein DR; Gottesman JE; Goldstein HR; Hull GW; Tran DN; Warsi GM; Lacerna LV
    Clin Genitourin Cancer; 2007 Mar; 5(4):271-7. PubMed ID: 17553207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.
    Michaelson MD; Kaufman DS; Lee H; McGovern FJ; Kantoff PW; Fallon MA; Finkelstein JS; Smith MR
    J Clin Oncol; 2007 Mar; 25(9):1038-42. PubMed ID: 17369566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Zoledronic acid improves bone mineral density in pediatric spinal cord injury.
    Ooi HL; Briody J; McQuade M; Munns CF
    J Bone Miner Res; 2012 Jul; 27(7):1536-40. PubMed ID: 22437628
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of zoledronic acid on reducing femoral bone mineral density loss following total hip arthroplasty: preliminary results of a prospective randomized trial.
    Scott DF; Woltz JN; Smith RR
    J Arthroplasty; 2013 Apr; 28(4):671-5. PubMed ID: 23142439
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
    Raje N; Terpos E; Willenbacher W; Shimizu K; García-Sanz R; Durie B; Legieć W; Krejčí M; Laribi K; Zhu L; Cheng P; Warner D; Roodman GD
    Lancet Oncol; 2018 Mar; 19(3):370-381. PubMed ID: 29429912
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Randomized Trial of Zoledronic Acid to Prevent Bone Loss in the First Year after Kidney Transplantation.
    Marques IDB; Araújo MJCLN; Graciolli FG; Dos Reis LM; Pereira RMR; Alvarenga JC; Custódio MR; Jorgetti V; Elias RM; Moysés RMA; David-Neto E
    J Am Soc Nephrol; 2019 Feb; 30(2):355-365. PubMed ID: 30606784
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between leptin and adiponectin concentrations in plasma and femoral and spinal bone mineral density in spinal cord-injured individuals.
    Sabour H; Norouzi Javidan A; Latifi S; Shidfar F; Vafa MR; Emami Razavi SH; Larijani B; Heshmat R
    Spine J; 2015 Jan; 15(1):1-9. PubMed ID: 24948038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial.
    Soo I; Siffledeen J; Siminoski K; McQueen B; Fedorak RN
    J Crohns Colitis; 2012 Aug; 6(7):777-86. PubMed ID: 22398088
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Denosumab increases sublesional bone mass in osteoporotic individuals with recent spinal cord injury.
    Gifre L; Vidal J; Carrasco JL; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
    Osteoporos Int; 2016 Jan; 27(1):405-10. PubMed ID: 26423406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bisphosphonates Alleviate Bone Loss in People with Acute Spinal Cord Injury：A Systematic Review and Meta-Analysis.
    Ma Z; Ma M; He Y; Sun H; Yang B; Dong H; Wang Y
    World Neurosurg; 2023 Feb; 170():e584-e595. PubMed ID: 36410707
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trabecular bone microarchitecture is deteriorated in men with spinal cord injury.
    Modlesky CM; Majumdar S; Narasimhan A; Dudley GA
    J Bone Miner Res; 2004 Jan; 19(1):48-55. PubMed ID: 14753736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional electrical stimulation (FES)-assisted rowing combined with zoledronic acid, but not alone, preserves distal femur strength and stiffness in people with chronic spinal cord injury.
    Fang Y; Morse LR; Nguyen N; Battaglino RA; Goldstein RF; Troy KL
    Osteoporos Int; 2021 Mar; 32(3):549-558. PubMed ID: 32888047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Letter to the Editor Regarding "Durability and Delayed Treatment Effects of Zoledronic Acid on Bone Loss After Spinal Cord Injury: A Randomized, Controlled Trial".
    Singhania P; Bhattacharjee R
    J Bone Miner Res; 2022 Jan; 37(1):167-168. PubMed ID: 34542188
    [No Abstract]   [Full Text] [Related]  

  • 37. Reply to Letter to the Editor Regarding "Durability and Delayed Treatment Effects of Zoledronic Acid on Bone Loss After Spinal Cord Injury: A Randomized, Controlled Trial".
    Edwards WB; Haider IT; Simonian N; Barroso J; Schnitzer TJ
    J Bone Miner Res; 2022 Jan; 37(1):169-170. PubMed ID: 34633107
    [No Abstract]   [Full Text] [Related]  

  • 38. The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis.
    Campbell SC; Bhoopalam N; Moritz TE; Pandya M; Iyer P; Vanveldhuizen P; Ellis NK; Thottapurathu L; Garewal H; Warren SR; Friedman N; Reda DJ
    Urology; 2010 May; 75(5):1138-43. PubMed ID: 20303574
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid.
    Brown JE; Ellis SP; Lester JE; Gutcher S; Khanna T; Purohit OP; McCloskey E; Coleman RE
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5406-10. PubMed ID: 17875770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Calcaneal quantitative ultrasound compared with hip and femoral neck dual-energy x-ray absorptiometry in people with a spinal cord injury.
    Schnitzer TJ; Wysocki N; Barkema D; Griffith J; Lent V; Romba M; Welbel R; Bhuva S; Manyam B; Linn S
    PM R; 2012 Oct; 4(10):748-55. PubMed ID: 22841967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.